Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral route
|
| gptkbp:approvedBy |
gptkb:non-small_cell_lung_cancer
gptkb:cancer melanoma vemurafenib in 2011 |
| gptkbp:ATCCode |
gptkb:L01XE
|
| gptkbp:combinationTherapy |
gptkb:MEK_inhibitors
|
| gptkbp:contraindication |
pregnancy
severe hepatic impairment |
| gptkbp:developedBy |
multiple pharmaceutical companies
|
| gptkbp:discoveredIn |
2000s
|
| gptkbp:example |
gptkb:encorafenib
gptkb:dabrafenib gptkb:sorafenib gptkb:vemurafenib |
| https://www.w3.org/2000/01/rdf-schema#label |
RAF inhibitors
|
| gptkbp:mechanismOfAction |
inhibit RAF/MEK/ERK pathway
|
| gptkbp:metabolism |
liver
|
| gptkbp:resistantTo |
activation of alternative pathways
secondary mutations in BRAF |
| gptkbp:sideEffect |
gptkb:cutaneous_squamous_cell_carcinoma
fatigue skin rash arthralgia |
| gptkbp:target |
RAF kinases
|
| gptkbp:targetGene |
gptkb:ARAF
gptkb:BRAF gptkb:CRAF |
| gptkbp:usedFor |
gptkb:cancer
|
| gptkbp:bfsParent |
gptkb:MAPK/ERK_pathway
|
| gptkbp:bfsLayer |
5
|